



Advancing cancer screening: Integrating multi-cancer early detection testing into your practice

Join us to discuss:

- Screening for many of the deadliest cancers that currently lack recommended screening options
- Clinical validation and real-world clinical experience
- Case studies that demonstrate the potential impact on patient care
- Implementing and experience in clinical practice



PRESENTER:
Rachael Schmidt, DNP, ARRN,
AOCNP
Medical Science Liaison
GRAIL

Rachael is a board-certified family nurse practitioner and Medical Science Liaison at GRAIL based in Omaha with over 15 years of healthcare experience. She earned her Bachelor of Science in Nursing from Creighton University, her Family Nurse Practitioner degree from Clarkson College, and her Doctor of Nursing Practice degree from the University of Nebraska Medical Center. Before joining GRAIL, Dr. Schmidt served in leadership roles at Nebraska Medicine and the Fred & Pamela Buffett Cancer Center, where she developed and led innovative programs focused on cancer risk, cancer screening, and cancer survivorship.

Dr. Schmidt's family includes her husband (Blake), their two sons (Ari & Luca), two dogs, and a few more farm animals than planned. Outside of work, she enjoys spending time with her family and golfing.

Wednesday
October 14, 2026
5:30 – 8:00 PM

Presentation to begin at 6:00

Location:
<https://lakeelmoinn.com/>
3442 Lake Elmo Ave N.
Lake Elmo, N. 55042

.....

RSVP HERE



The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.

Important Safety Information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information: The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.